Gatifloxacin ndamustine D4 The favorable pharmacokinetic profile of

The favorable pharmacokinetic profile of TAS-116 is reflected in its dose-dependent antitumor activity

BKM120 hydrochloride

4(1):e00558-12

2-dichloro-N-[(1R

InChi: InChI=1S/C15H11NS/c1-3-7-13-10(5-1)12-9-17-14-8-4-2-6-11(14)15(12)16-13/h1-8

Gatifloxacin ndamustine D4 The favorable pharmacokinetic profile ofGatifloxacin is an antibiotic of the fourth generation fluoroquinolone family that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. Gatifloxacin is a fluoroquinolone antibiotic, with potent activity against Gram negative and Gram positive bacteria. Bristol Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections. Allergan produces it in eye drop formulation under